Why Milestone Pharmaceuticals Stock Wilted on Wednesday

Milestone Pharmaceuticals reported just $238,000 in first-quarter Cardamyst sales, far below the more than $56 million analyst consensus, while its net loss widened to over $26 million or $0.20 per share from under $20.8 million a year ago. Commercial spending rose 52% year over year as the newly launched FDA-approved nasal spray had only about 600 prescriptions filled by the end of April. The company still has nearly $184 million in cash and runway into the second half of 2027, but near-term investor sentiment is likely pressured.

Analysis

MIST’s print is less a one-quarter miss than a market test of whether a niche launch can self-propagate without a broad primary-care funnel. The key second-order issue is not the initial script count, but the slope of acceleration: in rare-event acute care, adoption typically hinges on specialist enthusiasm, payer access, and ER-to-outpatient referral inertia, so the next 2-3 quarters will determine whether the product is a slow burn or a trapped-launch story. The current selloff looks like the market re-rating the stock from “commercial launch optionality” to “execution-dependent financing overhang,” which can compress multiples even if the product ultimately works.

The most important positive is runway, but that is also a subtle source of complacency: a cash-rich biotech can afford to be patient, yet patience often masks weak initial demand until the setup for the next capital raise becomes unavoidable. If scripts do not inflect meaningfully by mid-year, the probability rises that management leans harder into promotional spend, which extends the cash runway mathematically while worsening capital efficiency and delaying proof of demand. That dynamic tends to pressure the stock in a stair-step pattern rather than a one-time drawdown.

Consensus is likely overfocusing on the launch miss and underestimating how hard it is to dislodge entrenched acute-treatment behavior in a narrow indication. That said, the current move may still be too modest if commercialization stalls: for single-asset biotech, the valuation floor is usually set not by cash alone but by the market’s confidence in eventual peak sales, and that confidence can reset quickly when early scripts underwhelm. Conversely, a sharp rerating is possible if refill rates and prescriber concentration improve, because the base is so small that incremental evidence can move the stock disproportionately.

Key Decisions for Investors

• Short MIST into any post-earnings bounce over the next 1-3 weeks; risk/reward favors fade if scripts do not show clear sequential acceleration, with downside toward cash-adjusted valuation multiples if launch momentum stays weak.
• For longer-dated expression, buy MIST downside puts or put spreads 3-6 months out to capture the risk of a stalled launch and a credibility reset before the next material commercial update.
• Avoid chasing the long until there is evidence of refill velocity and broader prescriber adoption; the best risk/reward is after a confirmed inflection, not on hope that awareness eventually improves.
• Use a tight stop on any tactical long: if monthly script trajectory does not improve within 1-2 reporting cycles, the stock is likely to remain in a financing-overhang regime rather than a reacceleration regime.